Skip to main content
STOK
NASDAQ Life Sciences

Stoke Posts $73.6M Q3 Loss as Dravet Phase 3 Nears Readout, Cash Runs to Early 2028

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$26.36
Mkt Cap
$1.701B
52W Low
$20.32
52W High
$40.22
52W Position info
30% above low
Off High info
34% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

STOK sits 30% above its 52-week low of $20.32.

Summary

Stoke reported a Q3 2026 net loss of $73.6 million, or $1.08 per share, versus a $38.3 million loss a year earlier, as R&D spending jumped to $59.8 million on zorevunersen Phase 3 work and launch preparation. Revenue was $11.3 million, up modestly from $10.6 million and ahead of analyst expectations on its Biogen and Acadia collaborations. The company held $358.8 million in cash and marketable securities at September 30, which it says funds operations into early 2028 — covering the expected Phase 3 EMPEROR data readout in Q3 2027 and NDA submission in the second half of 2027. Enrollment in the primary analysis population is complete at 162 patients; roughly 110 have passed the Week 28 primary endpoint and about 20 have completed Week 52 with no discontinuations. The FDA-aligned NDA plan now uses a multicomponent Vineland-3 assessment for the cognition and behavior secondary endpoint. Biogen (BIIB) is the ex-US commercialization partner on zorevunersen; the update is neutral for BIIB. The key binary event remains the Q3 2027 EMPEROR readout.

At the time of this announcement, STOK was trading at $26.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $20.32 to $40.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

STOK - Latest Insights

STOK
Nov 03, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.99
Real-time Price: $26.94 info
Change: -$0.050 (-0.19%) info
Market Cap: $1.761B info
STOK
Oct 21, 2026, 4:42 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.68
Real-time Price: $26.94 info
Change: +$1.26 (+5%) info
Market Cap: $1.761B info
STOK
Oct 05, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $25.62
Real-time Price: $26.94 info
Change: +$1.32 (+5%) info
Market Cap: $1.761B info
STOK
Sep 03, 2026, 7:30 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $29.99
Real-time Price: $26.94 info
Change: -$3.05 (-10%) info
Market Cap: $1.761B info
STOK
Aug 03, 2026, 5:04 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $27.95
Real-time Price: $26.94 info
Change: -$1.01 (-4%) info
Market Cap: $1.761B info